Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status
Elínborg J. Ólafsdóttir(Icelandic Cancer Society), Laufey Tryggvadóttír(Icelandic Cancer Society), Maj‐Britt Jensen(Aarhus University Hospital), Åke Borg(Lund University), Bent Ejlertsen, Stefán Sigurðsson(University of Iceland), Maria Rossing(Rigshospitalet), Martin Nilsson(Lund University), Anne‐Vibeke Lænkholm, Rósa B. Barkardóttir(University of Iceland), Ida Marie Heeholm Sønderstrup(Zealand University Hospital), Anne‐Marie Gerdes(Copenhagen University Hospital), Anna L.V. Johansson(Karolinska Institutet), Eivind Hovig(Oslo University Hospital), Steven A. Narod(Women's College Hospital), Niklas Loman(Lund University), Guðríður H. Ólafsdóttir(Icelandic Cancer Society), Jón G. Jónasson(Reykjavík University), Óskar Þór Jóhannsson(National University Hospital of Iceland), Thomas van Overeem Hansen(University of Copenhagen)
Cited by 18
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k